Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia.

Abstract excerpt

PURPOSE OF REVIEW: Mutations in components of the spliceosome are the most common acquired lesions in myelodysplastic syndromes (MDS) and are frequently identified in other myeloid malignancies with a high rate of progression to acute myeloid leukemia (AML) including chronic myelomonocytic leukemia and primary myelofibrosis. The only curative option for these disorders remains allogeneic stem-cell...

Topics

Join the communities discussing this publication.

• Disease Management
• Disease Susceptibility
• Drug Development
• Leukemia, Myeloid, Acute
• Molecular Targeted Therapy